Cargando…
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Circulating tumor DNA (ctDNA) has emerged as a non-invasive “liquid biopsy” for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, comparing PIK3CA and TP53 mutations between tumor biopsies and pre-biopsy...
Autores principales: | Jimenez Rodriguez, Begona, Diaz Córdoba, Gema, Garrido Aranda, Alicia, Álvarez, Martina, Vicioso, Luis, Llácer Pérez, Casilda, Hernando, Cristina, Bermejo, Begoña, Julve Parreño, Ana, Lluch, Ana, Ryder, Matthew B., Jones, Frederick S., Fredebohm, Johannes, Holtrup, Frank, Queipo-Ortuño, María Isabel, Alba, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723048/ https://www.ncbi.nlm.nih.gov/pubmed/31394872 http://dx.doi.org/10.3390/jcm8081183 |
Ejemplares similares
-
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
por: Jiménez-Rodríguez, Begoña, et al.
Publicado: (2022) -
Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022) -
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023) -
Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients
por: Rodrigues, Patricia, et al.
Publicado: (2012) -
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)